Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.44 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468496 | 0.86 | IDO1 (0.37) | METAP2MAPTRAB9ACYP3A4SMN1; SMN2 | |
| SCHEMBL29454508 | 0.81 | MECP2 (0.62) | METAP2MEN1KDM4EALDH1A1MAPT | |
| SCHEMBL18176017 | 0.80 | METAP2 (0.37) | METAP2MEN1KDM4EALDH1A1MAPT | |
| SCHEMBL17900086 | 0.78 | GP6 (0.46) | MAOANPC1RAB9A | |
| SCHEMBL29484275 | 0.78 | GP6 (0.46) | MAOANPC1RAB9A | |
| SCHEMBL5496649 | 0.77 | IDO1 (0.56) | MEN1KDM4EMAPTHPGDKMT2A | |
| SCHEMBL3398767 | 0.77 | METAP2 (0.56) | METAP2 | |
| SCHEMBL22799656 | 0.77 | METAP2 (0.56) | METAP2ALDH1A1LMNACYP3A4HSD17B10 | |
| SCHEMBL16186300 | 0.77 | IDO1 (0.33) | METAP2 | |
| SCHEMBL3401179 | 0.77 | IDO1 (0.56) | METAP2KDM4EHPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888003-B2 | Method for producing 7-(pyrazole-3-yl) benzoxazoles | BASF AKTIENGESELLSCHAFT (DE) | 2005-05-03 | — | — | US | claimed |
| EP-1272486-B1 | METHOD FOR PRODUCING 7-(PYRAZOLE-3-YL) BENZOXAZOLES | BASF AG (DE) | 2004-08-11 | — | — | EP | claimed |
| US-20030050477-A1 | Method for producing 7-(pyrazole-3-yl) benzoxazoles | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-13 | — | — | US | claimed |
| EP-1272486-A1 | METHOD FOR PRODUCING 7-(PYRAZOLE-3-YL) BENZOXAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | claimed |
| WO-2001068644-A1 | METHOD FOR PRODUCING 7-(PYRAZOLE-3-YL) BENZOXAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | claimed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| WO-2021216812-A1 | GALACTOKINASE INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-6387919-B1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | GLAXO WELLCOME INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2001068644-A1 | METHOD FOR PRODUCING 7-(PYRAZOLE-3-YL) BENZOXAZOLES | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| US-4699915-A | ANTIULCER, ANTISECRETORY AGENTS | ISTITUTO DE ANGELI S.P.A. (IT) | 1987-10-13 | — | — | US | disclosed |
| CN-87100874-A | The 5-amino-1-phenyl-pyrazoles | — | 1987-08-19 | — | — | CN | disclosed |
| EP-0094727-A2 | Substituted heterocyclyl phenylformamidines, processes for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | METAP2 1889/4885MEN1 3309/4885KDM4E 2218/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | METAP2 1296/4885MEN1 4729/4885KDM4E 2840/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | METAP2 1296/4885MEN1 4729/4885KDM4E 2840/4885 |
| US-20030050477-A1 | Method for producing 7-(pyrazole-3-yl) benzoxazoles | F7, F9, TPO | METAP2 1717/4885MEN1 2227/4885KDM4E 2301/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | METAP2 1296/4885MEN1 4729/4885KDM4E 2840/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | METAP2 1664/4885MEN1 636/4885KDM4E 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.